Beta-blockers (All routes except ocular) (versus unexposed) updated on 12-17-2024

Neonatal hypotension

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14051
R55685		 Xiang - Labetalol, 2020 Neonatal hypotension during pregnancy (anytime or not specified) randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: Only chronic hypertension indication 8.02 [2.32;27.66] C 21/124   3/121 24 124
ref
S14183
R55597		 Yassen - Acebutolol, 1992 Neonatal hypotension during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 9.80 [0.44;219.26] C 3/11   0/11 3 11
ref
Total 2 studies 8.24 [2.61;26.04] 27 135
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Xiang - Labetalol, 2020Xiang - Labetalol, 2020 8.02[2.32; 27.66]2412486%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Yassen - Acebutolol, 1992Yassen - Acebutolol, 1992 9.80[0.44; 219.26]31114%ROB confusion: criticalROB selection: unclearROB classification: unclearROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 8.24[2.61; 26.04]271350.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 9.80[0.44; 219.26]311 -NAYassen - Acebutolol, 1992 1 case control studiescase control studies 0 RCTRCT 8.02[2.32; 27.66]24124 -NAXiang - Labetalol, 2020 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 9.80[0.44; 219.26]311 -NAYassen - Acebutolol, 1992 1 unexposed, sickunexposed, sick 8.02[2.32; 27.66]24124 -NAXiang - Labetalol, 2020 1 Tags Adjustment   - No  - No 9.80[0.44; 219.26]311 -NAYassen - Acebutolol, 1992 1   - Randomisation  - Randomisation 8.02[2.32; 27.66]24124 -NAXiang - Labetalol, 2020 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 9.80[0.44; 219.26]311 -NAYassen - Acebutolol, 1992 1   - Only chronic hypertension indication  - Only chronic hypertension indication 8.02[2.32; 27.66]24124 -NAXiang - Labetalol, 2020 1 MatchedMatched 9.80[0.44; 219.26]311 -NAYassen - Acebutolol, 1992 1 All studiesAll studies 8.24[2.61; 26.04]271350%NAXiang - Labetalol, 2020 Yassen - Acebutolol, 1992 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 9.80[0.44; 219.26]311 -NAYassen - Acebutolol, 1992 1 unexposed, sick controlsunexposed, sick controls 8.02[2.32; 27.66]24124 -NAXiang - Labetalol, 2020 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Magee (Neonatal hypotension)Magee (Neonatal hypotension) Out of scale-9.00[-9.00; -9.00]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 metaPregmetaPreg 8.24[2.61; 26.04]0%135----Xiang - Labetalol, 2020 Yassen - Acebutolol, 1992 20.510.01.0